Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a phase 1/2, multicenter, dose-finding and dose expansion study of OSE-279, a PD-1
blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas.